SI-BONE, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2018
January 07, 2019 at 05:30 pm IST
Share
SI-BONE, Inc. provided preliminary unaudited revenue guidance for the fourth quarter and full year 2018. For the quarter, revenue is expected to be in the range of $15.4 million -$15.6 million, reflecting growth of 12%-13% compared to the prior year period.
For the full year, revenue is expected to be in the range of $55.2 million -$55.4 million, reflecting growth of 15% over full year 2017.
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
SI-BONE, INC. 
